Healthy men test new version of cancer drug and how food affects it
NCT ID NCT05380947
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 trial enrolled 13 healthy men to compare two oral formulations of the drug BI 1810631. Researchers also tested how taking the drug with food or after multiple doses of the acid-reducer rabeprazole changes its absorption. The goal is to guide future dosing and formulation choices for this potential cancer treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BI 1810631 (Zongertinib)
- What this could lead to
- If successful, this study could help determine the best formulation and dosing instructions for BI 1810631 in future trials.
- What could go wrong
- This is a small, early-stage study in healthy volunteers, not patients. Results may not predict effects in people with the target disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Humanpharmakologisches Zentrum Biberach
Biberach, 88397, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test